Terns Pharmaceuticals Inc（TERN）のニュースとイベントTERNTerns Pharmaceuticals Inc

Merck Completes Acquisition of Terns Pharmaceuticals at $53 per Share

Merck announced the completion of the acquisition of Terns Pharmaceuticals. TERN-701 was recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase without the T315I mutation previously treated with two or more tyrosine kinase inhibitors. The BTD designation for TERN-701 is based on data from the ongoing Phase 1/2 CARDINAL trial. Merck completed the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Terns at a purchase price of $53.00 per share, without interest and subject to any applicable tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on May 4, 2026, 100,091,794 shares of Terns common stock were validly tendered and not validly withdrawn, representing approximately 86.36% of the total number of Terns' issued and outstanding shares of common stock as of such date and time. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck, on behalf of its subsidiary, will promptly pay for such shares. Following the completion of the tender offer, Merck completed the acquisition of Terns through a merger of Merck's wholly-owned subsidiary with and into Terns, with Terns being the surviving corporation, in which all shares of Terns common stock issued and outstanding at the effective time of the merger were converted into the right to receive cash equal to the $53.00 offer price per share, without interest and subject to any applicable tax withholding. At the completion of the merger, Terns became a wholly-owned subsidiary of Merck and Terns' common stock will no longer be listed or traded on the Nasdaq Global Select Market. The transaction is expected to be accounted for as an asset acquisition, resulting in a charge to research and development expense of approximately $5.8B or approximately $2.35 per share, included in both second quarter and full year 2026 GAAP and non-GAAP results. Additionally, GAAP and non-GAAP EPS are expected to be negatively impacted by approximately $0.12 per share in 2026, representing costs associated with advancing TERN-701 and costs of financing.

Terns Pharmaceuticals Receives Breakthrough Therapy Designation for TERN-701

Terns Pharmaceuticals announced that the FDA granted breakthrough therapy designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs.

Oppenheimer Downgrades Terns Pharmaceuticals to Perform

Oppenheimer downgraded Terns Pharmaceuticals (TERN) to Perform from Outperform after the company agreed to be acquired by Merck (MRK) for $53 per share.